Quince Therapeutics Regains Nasdaq Bid Price Compliance, MVLS Issue Remains
Summary
Quince Therapeutics has regained compliance with Nasdaq's minimum bid price rule, but still faces a delisting threat due to non-compliance with the Market Value of Listed Securities requirement.
Key Events
-
Regains Bid Price Compliance
On April 27, 2026, Quince Therapeutics received notification from Nasdaq that it has regained compliance with the minimum bid price requirement (Rule 5450(a)(1)), having maintained a closing bid price of $1.00 or greater for 10 consecutive business days.
-
Market Value of Listed Securities (MVLS) Non-Compliance Persists
The company has not yet regained compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement (Rule 5450(b)(2)(A)) and has until September 14, 2026, to do so.
-
Ongoing Delisting Concerns
Despite resolving the bid price issue, the company acknowledges there is no assurance it will regain MVLS compliance or maintain other applicable Nasdaq listing requirements.
Analysis
This 8-K confirms Quince Therapeutics has regained compliance with Nasdaq's minimum bid price requirement, removing an immediate delisting threat. However, the company explicitly states it has not yet regained compliance with the Market Value of Listed Securities (MVLS) requirement and has until September 14, 2026, to do so. This partial compliance update comes amidst ongoing efforts to address its financial viability, including a proposed reverse stock split and a previously disclosed "going concern" warning. Investors should monitor progress on the MVLS requirement and the outcome of the reverse stock split vote.
At the time of this filing, QNCX was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20M. The 52-week trading range was $0.80 to $45.50. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.